Acquisition Of Prostiva Radio Frequency Therapy (Narrative) (Details) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Sep. 06, 2011	Jun. 30, 2011
Business Acquisition [Line Items]
Term of Exclusive Worldwide License			10 years
Purchase price			$ 10,000,000
Market share percentage of BPH in office treatment	50.00%
Fair value of consideration to be paid to acquire Prostiva	7,000,000
Total initial licensing fee			1,000,000
Licensing fee paid			500,000
Purchase price, amount unpaid	5,100,000
Non-contingent consideration future cash payments			3,800,000
Contingent consideration, at fair value	1,471,000	2,862,000	2,700,000
Gain recognized related to fair value change of contingent consideration	1,400,000
Loss on change of non-contingent consideration.	933,000
Net impact of change in value of acquisition consideration	447,000	172,000
Impairment of long-lived assets	160,000
Goodwill	3,036,000	3,115,000
Value of goodwill for tax purpose			1,700,000
Cumulative transaction expense		391,000
Transaction expense		288,000		103,000
License costs to maintain patents	65,000
Monthly transition service fee	30,000
Prostiva [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets	(434,000)
Revenues	5,800,000	5,400,000
Developed Technology [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets	274,000
Customer Base [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets	95,000
Trademarks [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets	$ 65,000